European non-interventional post-authorization safety study related to serious cardiovascular events of myocardial infarction and stroke, and all-cause mortality for romosozumab by the EU-ADR Alliance First published 24/09/2020 Last updated 02/07/2024 EU PAS number:EUPAS35881 Study Ongoing